- Home
- BOLT vs LPCN Comparison
BOLT vs LPCN Comparison
Compare BOLT & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOLT
- LPCN
- Stock Information
- Founded
- BOLT 2015
- LPCN 1997
- Country
- BOLT United States
- LPCN United States
- Employees
- BOLT N/A
- LPCN N/A
- Industry
- BOLT Biotechnology: Pharmaceutical Preparations
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- BOLT Health Care
- LPCN Health Care
- Exchange
- BOLT Nasdaq
- LPCN Nasdaq
- Market Cap
- BOLT 16.8M
- LPCN 16.4M
- IPO Year
- BOLT 2021
- LPCN N/A
- Fundamental
- Price
- BOLT $0.40
- LPCN $3.17
- Analyst Decision
- BOLT Hold
- LPCN Strong Buy
- Analyst Count
- BOLT 5
- LPCN 1
- Target Price
- BOLT $1.13
- LPCN $10.00
- AVG Volume (30 Days)
- BOLT 146.3K
- LPCN 10.5K
- Earning Date
- BOLT 05-13-2025
- LPCN 03-13-2025
- Dividend Yield
- BOLT N/A
- LPCN N/A
- EPS Growth
- BOLT N/A
- LPCN N/A
- EPS
- BOLT N/A
- LPCN N/A
- Revenue
- BOLT $7,690,000.00
- LPCN $11,198,144.00
- Revenue This Year
- BOLT N/A
- LPCN N/A
- Revenue Next Year
- BOLT $77.45
- LPCN $37.31
- P/E Ratio
- BOLT N/A
- LPCN N/A
- Revenue Growth
- BOLT N/A
- LPCN N/A
- 52 Week Low
- BOLT $0.38
- LPCN $2.91
- 52 Week High
- BOLT $1.48
- LPCN $11.79
- Technical
- Relative Strength Index (RSI)
- BOLT 40.42
- LPCN 41.52
- Support Level
- BOLT $0.38
- LPCN $3.00
- Resistance Level
- BOLT $0.47
- LPCN $3.57
- Average True Range (ATR)
- BOLT 0.04
- LPCN 0.26
- MACD
- BOLT -0.00
- LPCN -0.00
- Stochastic Oscillator
- BOLT 18.81
- LPCN 23.29
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.